Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
Stockchase Opinions

Bruce Campbell (2)NeurochemNRM.TOCOMMENTJul 04, 2022

The name of the company was indistinct and this is the closest result in the data base. It is a biotech company focused on brain health. It acquired an AI company called Metro Mark. It is signing more and more deals with pharmaceutical companies for up-front and royalty payments.
N/A

Stock price when the opinion was issued

biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

SELL
He likes it, the only downside is that because the Japaneese market has risen 40% over the last year, it's a bit expensive right now. He suggests going to a different fund which is not so centered on the Japaneese market.
DON'T BUY
Looking at his relative performer chart, it's been an underperformer. Has negative money flow. In a very clear downtrend.
BUY
There has been a general selloff of biotech stocks. Still believe in this company.
DON'T BUY
Feels it's a little pricey at these levels given where they are in the development of their program. Have some interesting programs.
BUY
Has been moving sideways which, for a biotech, is not too bad. The company has good backing. Should see considerable upside.
PAST TOP PICK
(A top pick Sept 9/03. Up100 %.) Still likes. The market opportunity is so big, would still buy at this price.
PAST TOP PICK
(A top pick Sept 9/03. Up 58%.) As a potential treatment for Alzheimer's. Good technology. Has some US financing which will get US investors interested.
TOP PICK
Into phase 3 trial. All cashed up. Will start to be getting attention.
BUY
Has a very strong range of products.
HOLD
Has gone up quite well and may stay level for awhile.
TOP PICK
Likes the managemnt. Big financial support.